ADFs: Gimmick or Godsend?

While abuse deterrent formulations purportedly meet the FDA demand for safer opioid medications, their expense has been rarely supported by third party payors. Dr. Schatman reviews the reimbursement picture, the evidence for their effectiveness, and how prescribers can best respond.